{"id":"W2478115115","doi":"10.1200/jco.2013.31.15_suppl.9009","title":"Clinical efficacy and safety of lambrolizumab (MK-3475, Anti-PD-1 monoclonal antibody) in patients with advanced melanoma.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rash; Ipilimumab; Internal medicine; Adverse effect; Progressive disease; Gastroenterology; Melanoma; Toxicity; Phases of clinical research; Surgery; Disease; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007988114,0.0003015838,0.0006318854,0.0002089952,0.0001677253,0.0003358781,0.0002354346,0.0003602076,0.0009828527],"category_scores_gemma":[0.0007708902,0.0001893858,0.0003652216,0.0001668891,0.0002698818,0.0002826662,0.000154542,0.0007245785,0.0003298447],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005290217,"about_ca_system_score_gemma":0.0003916242,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003420478,"about_ca_topic_score_gemma":0.0007966753,"domain_scores_codex":[0.9998211,0.0000743666,0.0000150776,0.00003080733,0.000034984,0.00002356491],"domain_scores_gemma":[0.9996792,0.00008710536,0.00008596258,0.00001458368,0.0000221122,0.0001110018],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2041434,0.01181755,0.2573247,0.001034114,0.00064717,0.001727222,0.0005685659,0.003784667,0.1041532,0.0002136707,0.005108687,0.409477],"study_design_scores_gemma":[0.06709731,0.3671201,0.5303065,0.0001240394,0.0008374861,0.004083113,0.0001327668,0.00500595,0.01282032,0.0003558547,0.01207538,0.00004123026],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9955422,0.002653991,0.0001518863,0.0001676543,0.00001678923,0.0001550564,0.000192888,0.00002012242,0.001099486],"genre_scores_gemma":[0.9982109,0.0005852951,0.0002894236,0.0001759732,0.00004489849,0.00007092131,0.000319073,0.000003388933,0.0003000726],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0009828527,"threshold_uncertainty_score":0.004224539,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03772999889311207,"score_gpt":0.4213025658856346,"score_spread":0.3835725669925226,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}